Evolution and Revolution of Radioiodine Refractory Thyroid Cancer
If you attended the Evolution and Revolution of Radioiodine Refractory Thyroid Cancer session held Saturday, May 6, 2017 at the AACE Annual Meeting in Austin, TX, please proceed to attempt this assessment for ABIM Maintenance of Certification (MOC) credit. To begin, select the red 'Take Course' tab. You must be logged in to access the assessment.
- AACE Members: login with the same username/password used for the AACE website.
- Non-AACE Members: login using the non-member portal if you have an existing non-member account OR create an account if you are new to the AACE Education website.
Once logged in, you will be prompted to enter the access code you received onsite (found on page 7 of the Schedule-at-a-Glance). If you need assistance, please contact email@example.com.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Only those who receive a passing score will be eligible for MOC credit. Please allow two weeks for MOC points to appear within your account on the ABIM website.
Participation information will be shared with the American Board of Internal Medicine (ABIM) through the Accreditation Council for Continuing Medical Education (ACCME) Program and Activity Reporting System (PARS).
- Define the various characteristics of radioiodine refractory thyroid cancer in clinical practice
- Select among approved and novel systemic treatment options for patients with radioiodine refractory thyroid cancer
- Identify patients who might participate in clinical trials of investigational therapies
Felice Caldarella, MD; Steven I. Sherman, MD
- 0.75 MOC